Sai Parenterals Ltd
NSE: SAIPARENT BSE: 544742Pharma
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
₹480
52W: ₹400 — ₹526
PE 205 · Book ₹0 · +0% vs bookMarket Cap₹2,123 Cr
Stock P/E205Price to Earnings
ROCE13.9%Return on Capital
ROE12.2%Return on Equity
Div. Yield0%Face Value ₹5
Weaknesses
- −Company has a low return on equity of 12.9% over last 3 years.
- −Company has high debtors of 254 days.
Shareholding Pattern
Promoters51.16%
FIIs5.73%
DIIs12.86%
Public30.25%
| Category | Mar 2026 | Apr 2026 |
|---|---|---|
| Promoters | 51.16% | 51.16% |
| FIIs | 5.73% | 5.73% |
| DIIs | 12.86% | 12.86% |
| Public | 30.25% | 30.25% |
AI Insights
Revenue Trend
Mar 2025 revenue at ₹124Cr, up 8.8% YoY. OPM at 22%.
Debt Position
Borrowings at ₹72Cr. Debt-to-equity ratio: 0.92x. Moderate leverage.
Margin & Efficiency
ROCE improving from 0% (Mar 2023) to 14% (Mar 2025). Working capital days: 59.
Valuation
PE 205x with 13.9% ROCE. Price is N/A% above book value of ₹0. Dividend yield: 0%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Monitoring Agency Report 13 May - Monitoring agency report for quarter ended 31 March 2026 shows no deviation in IPO proceeds utilization.
- Results-Delay in Financial Results 22 Apr - Sai Parenterals delays results submission to 15 May 2026; audited FY26 results due by 30 May 2026.
- Board Meeting Outcome for Outcome Of Board Meeting 20 Apr - Board approved up to AUD 1.75 million loan to Sai Singapore Pte. Ltd. on April 20, 2026.
- Board Meeting Intimation for INTIMATION OF BOARD MEETING WHICH IS PROPOSED TO BE HELD ON 20TH OF APRIL 2026 14 Apr - Board meeting on April 20, 2026 to consider investing in or lending to Noumed Pharmaceuticals Pty Limited.
- Closure of Trading Window 6 Apr - Trading window closed from April 2, 2026 for Q3 and FY26 results board meeting.